Work Here?
Overview
PostEra.ai speeds up medicinal chemistry by applying machine learning to design and plan synthesis for drug candidates, accelerating the Design-Make-Test cycle in drug discovery. Its AI tools propose molecular designs and viable synthesis routes to help researchers optimize properties and iterate experiments faster. It generates revenue mainly through large partnerships and collaborations with pharma companies and government programs, such as a Pfizer AI Lab deal and NIH antiviral collaboration. The goal is to shorten time and reduce cost in drug discovery by leveraging AI-assisted chemistry and sustained industry collaborations.
About PostEra
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$24.1M
Headquarters
Santa Clara, California
Founded
2019
Get referred to PostEra
See people who can refer or advise you
Simplify's Take
What believers are saying
- PostEra's January 2025 Pfizer expansion added ADCs and $12M upfront cash.
- PostEra's July 2026 site lists wholly owned PCOS, reproductive endocrinology, and fertility programs.
- PostEra still hires in 2026, signaling capital access and operational continuity despite biotech weakness.
What critics are saying
- Pfizer dominates PostEra revenue concentration; a 2025 repricing would crush growth.
- PostEra's pipeline is early-stage; if 2026 PCOS trials slip, internal value collapses.
- Specialized AI drug discovery faces commoditization from Optibrium, Schrödinger, and pharma's in-house teams.
What makes PostEra unique
- PostEra's Proton platform ties generative chemistry to synthesis-aware design, reducing dead-end molecules.
- Pfizer renewed the partnership on January 7, 2025, expanding AI Lab to $610M.
- PostEra built durable pharma credibility through NIH antivirals and Amgen collaborations, plus open-science Moonshot.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$24.1M
Above
Industry Average
Funded Over
2 Rounds
Y CombinatorIndustry standards
Benefits
Performance Bonus
Stock Options
Professional Development Budget
Conference Attendance Budget
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 4%PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster.
Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, today announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
What You Should Know: PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and ... Read More
PostEra, a biotechnology company specialising in machine learning for drug discovery, today announced that it has received a grant of £100,000 from the independent medical charity LifeArc to support an international effort to rapidly develop a potential antiviral candidate for COVID-19.
There are no jobs for PostEra right now.
Find jobs on Simplify and start your career today
About PostEra
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$24.1M
Headquarters
Santa Clara, California
Founded
2019
There are no jobs for PostEra right now.
Find jobs on Simplify and start your career today